CD274 and diffuse large B-cell lymphoma: In Phase 2, we assessed the CR rate of Isa + Cemi in anti‐PD‐1/PD‐L1 naïve patients with cHL (Cohort A1) and objective response rate (ORR) in anti‐PD‐1/PD‐L1 progressors with cHL (Cohort A2), anti‐PD‐1/PD‐L1 naïve patients with DLBCL (Cohort B), and anti‐PD‐1/PD‐L1 naïve patients with PTCL (Cohort C).